Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Net Margin (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Net Margin for 12 consecutive years, with 68.28% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 12780.0% to 68.28% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 832.66% through Dec 2025, down 9609.0% year-over-year, with the annual reading at 832.66% for FY2025, 9160.0% down from the prior year.
  • Net Margin hit 68.28% in Q4 2025 for Coherus Oncology, down from 77.66% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 7405.16% in Q1 2024 to a low of 233.47% in Q1 2023.
  • Historically, Net Margin has averaged 518.33% across 5 years, with a median of 60.89% in 2021.
  • Biggest five-year swings in Net Margin: surged 763863bps in 2024 and later plummeted -752584bps in 2025.
  • Year by year, Net Margin stood at 62.26% in 2021, then crashed by -108bps to 129.79% in 2022, then surged by 33bps to 87.03% in 2023, then soared by 32bps to 59.52% in 2024, then surged by 215bps to 68.28% in 2025.
  • Business Quant data shows Net Margin for CHRS at 68.28% in Q4 2025, 77.66% in Q3 2025, and 3341.42% in Q2 2025.